Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5827353 | European Journal of Pharmacology | 2015 | 5 Pages |
Abstract
Nalbuphine, a kappa-opioid agonist and mu-opioid partial agonist, has been used as an analgesic or an adjuvant with morphine to attenuate the development of morphine dependence and rewarding effect. In this study, we investigated the effect of nalbuphine on tramadol rewarding effect and antinociception. Using the conditioned place preference (CPP) paradigm in mice, we demonstrated that co-administration of nalbuphine (7Â mg/kg, s.c.) with tramadol (70Â mg/kg, s.c.) during conditioning completely blocked the CPP induced by tramadol. Co-administration of nalbuphine blocked the increase in dopamine level in the nucleus accumbens induced by tramadol. These actions were accompanied by an increase rather than attenuation of the antinociceptive effect of tramadol. These results suggest that nalbuphine could have a great potential as a pharmacotherapy for tramadol abuse.
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Rasha Abdel-Ghany, Mahmoud Nabil, Mohamed Abdel-Aal, Waleed Barakat,